25,962 Shares in Harrow, Inc. (NASDAQ:HROW) Acquired by American Century Companies Inc.

American Century Companies Inc. acquired a new stake in Harrow, Inc. (NASDAQ:HROW - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 25,962 shares of the company's stock, valued at approximately $871,000. American Century Companies Inc. owned about 0.07% of Harrow as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of HROW. JPMorgan Chase & Co. boosted its holdings in Harrow by 443.1% in the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock valued at $10,717,000 after acquiring an additional 194,480 shares during the last quarter. Barclays PLC raised its holdings in Harrow by 301.9% in the third quarter. Barclays PLC now owns 52,593 shares of the company's stock worth $2,365,000 after purchasing an additional 39,506 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Harrow during the third quarter worth $1,469,000. Great Lakes Advisors LLC acquired a new position in shares of Harrow in the 4th quarter valued at $972,000. Finally, SG Americas Securities LLC raised its stake in Harrow by 158.5% during the 4th quarter. SG Americas Securities LLC now owns 30,689 shares of the company's stock worth $1,030,000 after buying an additional 18,815 shares during the period. Institutional investors and hedge funds own 72.76% of the company's stock.

Analysts Set New Price Targets

HROW has been the topic of several recent analyst reports. B. Riley cut their price objective on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. HC Wainwright reaffirmed a "buy" rating and issued a $57.00 price objective on shares of Harrow in a research report on Monday, March 31st.

Harrow Stock Up 0.2 %

Shares of HROW stock traded up $0.05 during trading on Thursday, reaching $23.40. The company's stock had a trading volume of 33,116 shares, compared to its average volume of 466,219. The company has a market cap of $834.13 million, a price-to-earnings ratio of -24.89 and a beta of 0.46. Harrow, Inc. has a one year low of $9.86 and a one year high of $59.23. The business has a fifty day moving average price of $26.44 and a 200-day moving average price of $35.99. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.14. The company had revenue of $66.83 million during the quarter, compared to analysts' expectations of $66.01 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. Analysts anticipate that Harrow, Inc. will post -0.53 earnings per share for the current year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.